Ascendis Pharma Achieves Strong Q3 2025 Financial Results Amid Product Expansion

An announcement from Ascendis Pharma ( (ASND) ) is now available.

Ascendis Pharma reported strong financial results for the third quarter of 2025, with total revenue reaching €213.6 million, a significant increase from the previous year. The company achieved an operating profit of €11.0 million, driven by the successful global launch of YORVIPATH and the continued uptake of SKYTROFA. The company is advancing its pipeline with TransCon CNP under FDA priority review for treating achondroplasia in children, with a decision expected by the end of November 2025. Ascendis is also expanding its product labels and conducting trials to support further growth, indicating a positive outlook for future innovation and market expansion.

The most recent analyst rating on (ASND) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.

Spark’s Take on ASND Stock

According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.

Ascendis Pharma’s stock score is driven by strong earnings call highlights and positive technical indicators. However, financial performance and valuation concerns due to ongoing losses and reliance on debt financing weigh down the overall score.

To see Spark’s full report on ASND stock, click here.

More about Ascendis Pharma

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, focusing on developing innovative therapies for rare diseases. The company is known for its TransCon technology platform, which is used to create long-acting prodrugs. Their primary products include YORVIPATH, used for hypoparathyroidism, and SKYTROFA, for growth hormone deficiency.

Average Trading Volume: 417,638

Technical Sentiment Signal: Buy

Current Market Cap: $11.87B

For a thorough assessment of ASND stock, go to TipRanks’ Stock Analysis page.